Lodo Therapeutics Corporation is a drug discovery and development company focused on the creation of novel therapeutics derived from nature that will impact patients around the world. Lodo seeks to work in partnership with global pharmaceutical companies and world leading non-governmental organizations (NGO's) to tackle some of the greatest challenges in human health: drug-resistant microbial infections and cancers.
Lodo Therapeutics was created to pursue the scientific vision of Dr. Sean Brady at Rockefeller University and co-founded by Dr. David Pompliano (Ex. Merck, Revolution Medicine). Lodo Therapeutics identifies and produces bioactive natural products directly from the microbial DNA sequence information contained in soil. Lodo believes that the potential cures for a number of deadly and/or debilitating diseases literally lie at our feet. Information encoded in bacterial genomes, not experimental serendipity, drives our discovery of new medicines. Not constrained by traditional culture-based approaches to natural products drug discovery, Lodo Therapeutics has unlocked a vast trove of overlooked compounds evolutionarily selected for processes essential for life.
Lodo Therapeutics, an Accelerator Life Science Partners-backed entity, is headquartered in New York City. The company's lab and offices are located in the Alexandria Center for Life Science, New York City's first and only premier life science park.
The initial management of Lodo Therapeutics will be provided by Accelerator Life Science Partners' core management team of talented professionals with deep investment, operational and scientific expertise. For more information visit: Accelerator — Senior Leadership
Senior Vice President, R&D
Director of Research
Eli Lilly and Company
ARCH Venture Partners
Accelerator Life Science Partners
Alexandria Real Estate Equities, Inc.